Introduction {#s0005}
============

*Acanthamoeba* spp. are free-living, ubiquitous protozoa found mainly in humid soil and in water reservoirs. They are the causative agents of *Acanthamoeba* keratitis (AK), a vision-threatening corneal infection first reported in 1973 in the United States [@b0005]. *Acanthamoeba* trophozoites are relatively responsive to many therapies, while *Acanthamoeba* cysts are well suited to survive extreme environmental conditions, including medications. The highly resistant cyst form makes AK treatment difficult [@b0010].

AK has a high cure rate if diagnosis could be made as early as possible [@b0015]. If diagnosis is delayed, AK can become refractory to traditional treatment, particularly at later stages when the infection penetrates the deep stroma. There is no consensus on the treatment for AK till now. A recent study compared the therapeutic effect of different topical antiamoebic agents (0.02% polyhexamethylene biguanide (PHMB) monotherapy, 0.02% PHMB + 0.1% diamidine, 0.02% PHMB + 0.02% chlorhexidine + 0.1% diamidine, and 0.1% diamidine monotherapy), which showed that 0.02% PHMB monotherapy for the initial treatment of AK is as effective as biguanide + diamidine combination therapy [@b0020]. Nevertheless, current conventional therapies for AK are 0.02% biguanide (PHMB or chlorhexidine) in combination with a 0.1% diamidine (propamidine isethionate or hexamidine) applied hourly for at least 1 week and then tapered weekly according to the patient's clinical response [@b0025], [@b0030]. For patients with late diagnosis and poor drug responses, alcohol-assisted epithelial debridement can be performed as an adjuvant therapy to avoid therapeutic keratoplasty [@b0030].

Intrastromal injection of antimicrobial agents may be promising adjunctive treatments for deep recalcitrant microbial keratitis, which responds poorly to conventional treatment modalities [@b0035], [@b0040], [@b0045], [@b0050]. However, this strategy has not been tested in AK due to suspicions of drug toxicity. The concentration-dependent corneal toxicities of antiamoebic agents have been previously reported [@b0055], but their toxicity after corneal intrastromal injection remains untested. Therefore, in this study, we have investigated corneal toxicity in rabbit eyes after intrastromal injection of PHMB and propamidine isethionate, to determine safe concentrations for AK treatment. With safe dosages, intrastromal injection of PHMB or propamidine isethionate could represent promising adjuvant therapies for deep AK.

Material and methods {#s0010}
====================

All animal procedures were performed in accordance with the Association for Research in Vision and Ophthalmology statement for the use of animals in ophthalmic and vision research and were approved by the University Institutional Animal Care and Use Committee of National Cheng Kung University (NCKU).

Preparation of PHMB and propamidine isethionate {#s0015}
-----------------------------------------------

Two antiamoebic agents were used in our study. PHMB is a synthetic cationic polymer composed of repeating basic biguanide units connected by hexamethylene hydrocarbon chains [@b0060] and propamidine isethionate is a polyether compound known as bis(4-guanidinophenyl) ether of propane-1,3-diol, which works through inhibiting synthesis of DNA, RNA, phospholipids, and proteins [@b0065]. PHMB (Cosmocil CQ 20%, Avecia Biocides, U.K.) was diluted to 0.02 and 0.01%. Propamidine isethionate (0.1%; Brolene eyedrops; Sanofi-Aventis, Australia) was used as supplied, and also diluted to 0.05%.

Animals {#s0020}
-------

The right eyes of 12 New Zealand white rabbits were intrastromally injected with 0.1 mL of 0.02% PHMB, 0.01% PHMB, 0.1% propamidine isethionate, or 0.05% propamidine isethionate (n = 3 per treatment). The left eyes served as controls and were subjected to intrastromal injection of 0.1 mL phosphate-buffered saline (PBS).

Corneal intrastromal injection {#s0025}
------------------------------

Rabbits were anesthetized by an intramuscular injection of ketamine hydrochloride (20 mg/kg) and xylazine (10 mg/kg) before intrastromal injection. Topical anesthesia was provided using Alcaine (proparacaine hydrochloride 0.5%; Alcon, Fort Worth, TX). Under a surgical microscope, intrastromal injection of 0.1 mL of solution was performed by 30-gauge needle at three different sites in the paracentral corneal stroma. The animals were sacrificed 7 days after intrastromal injection by intravenous injection of a lethal dose of pentobarbital. The corneal buttons were harvested and examined by slit lamp microscopy, specular microscopy (SM), Hematoxylin and eosin (H&E) staining, scanning electron microscopy (SEM), Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay, and cell viability test.

Isolation and culture of corneal cells {#s0030}
--------------------------------------

Isolated rabbit corneal endothelial cells were incubated with 0.5 g/L trypsin-0.2 g/L ethylenediaminetetraacetic acid (Invitrogen-Gibco, Karlsruhe, Germany) at 37 °C for 10 min. Descemet's layer was removed by mechanical dissection under the microscope. Endothelial cells were cultured in 25 cm^2^ culture flasks containing Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich), 24 mg/mL adenine, 4 mM L-glutamine, 1% antibiotic solution (Invitrogen-Gibco), and growth factors (0.4 mg/mL hydrocortisone, 1.3 ng/mL triiodothyronine, 8 ng/mL cholera toxin, and 5 mg/mL insulin). The culture medium was changed every 3 days. To isolate rabbit corneal stromal keratocytes, the corneal epithelial and endothelial layers were removed carefully by mechanical scraping. The remaining stroma was cut into small explants approximately 3 mm in size, which were placed in plastic culture dishes to allow keratocyte growth. The growth media was DMEM supplemented with 10% FCS, 4 mM L-glutamine, and 1% antibiotic solution. The culture medium was changed every 3 days.

Examinations {#s0035}
============

Slit lamp microscopy {#s0040}
--------------------

The rabbits' corneas were examined by slit lamp microscopy to evaluate the presence of possible corneal changes, including corneal edema, epithelial erosion, corneal neovascularization, and corneal haze 7 days after intrastromal injection.

Specular microscopy (SM) {#s0045}
------------------------

Endothelial cell counts were measured on a Konan KSS-EB10 SM (Konan Medical USA, Irvine, CA) 7 days after intrastromal injection. The endothelial cell density, coefficient of variation (CV), and percentage of hexagonal cells (6A%) were determined in at least 50 endothelial cells per replicate.

Hematoxylin and eosin (H&E) staining {#s0050}
------------------------------------

We prepared 6-μm sections from corneas, stained them with H&E, and imaged them under a light microscope (E-800 Leica, Solms, Germany) equipped with a digital video camera (Nikon DS-Ri1, Tokyo, Japan).

Scanning electron microscopy (SEM) {#s0055}
----------------------------------

Corneal specimens were rinsed with PBS and immediately immersed in 2.5% glutaraldehyde at 4 °C for at least 24 h. The specimens were then rinsed with Milli-Q (MQ) water three times for 5 min each, and transferred to 1% tannic acid for 60 min at room temperature. The specimens were subsequently rinsed with MQ water three times for 5 min each. The samples were then dehydrated by immersion in a graduated ethanol series according to the following scheme (5 min each): 30% (once), 50% (once), 70% (once), 95% (twice), and 100% (three times). After dehydration, specimens were soaked in hexamethyldisilazane for 15 min, then placed in an empty desiccator and left in a fume hood overnight at room temperature. The specimens were coated with gold and ultrastructural changes were evaluated using an SEM at different magnifications.

Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay {#s0060}
--------------------------------------------------------------------------------

The TUNEL assay was used to quantitatively detect apoptosis in the corneas, using the Roche In Situ Cell Death Detection Kit, AP. Briefly, dewaxed and rehydrated tissue sections were incubated with Proteinase K working solution for 15--30 min at room temperature. Slides were rinsed with PBS and the area around the samples was dried with filter paper. The lid was added and the cells were incubated in TUNEL reaction mixture (50 µL per well) for 60 min at 37 °C in the dark. The slides were subsequently rinsed three times with PBS. The samples were observed under a fluorescence microscope using an excitation wavelength in the range of 450--500 nm and detection in the range of 515--565 nm (green). TUNEL-positive nuclei appeared green, while TUNEL-negative nuclei appeared blue.

Cell viability assay {#s0065}
--------------------

The viability of keratocytes and endothelial cells was assessed using the WST-1 (Water-Soluble Tetrazolium salt-1) assay (Takara Bio, Shiga, Japan). We prepared a cell suspension containing 0.1--1.0 × 10^6^ cells/mL in medium, added 100 µL of the suspension to the wells of a 96-well cell culture plate, and incubated the plate for 24--96 h at 37 °C and 5% CO~2~ in a humidified incubator for cell culture. Then, 10 µL of CytoSelect™ WST-1 Cell Proliferation Assay Reagent was added to each well, and the plate incubated at 37 °C and 5% CO~2~ for 0.5--4 h. Absorbance was measured at 450 nm using a plate reader.

Statistical analysis {#s0070}
--------------------

Statistical significance was analyzed using the Student's *t*-test. *P* values \< 0.05 were considered statistically significant. All data are expressed as the mean ± SD. Statistical analyses were performed using GraphPad Prism 6.0 software.

Results {#s0075}
=======

Slit lamp examination {#s0080}
---------------------

Eyes were evaluated 7 days after intrastromal injection. Corneas injected with PBS were clear in appearance ([Fig. 1](#f0005){ref-type="fig"}A), while corneal edema, epithelial erosion, and severe neovascularization were observed with 0.02% PHMB treatment ([Fig. 1](#f0005){ref-type="fig"}B). Corneas injected with 0.01% PHMB were also clear under slit lamp examination ([Fig. 1](#f0005){ref-type="fig"}C). For propamidine isethionate, the 0.1% solution resulted in corneal edema with epithelial erosion, but no neovascularization was observed ([Fig. 1](#f0005){ref-type="fig"}D). No corneal edema or erosion was observed with 0.05% propamidine isethionate ([Fig. 1](#f0005){ref-type="fig"}E).Fig.1Slit lamp, H&E, and SEM analysis. Slit lamp results from control (A), PHMB-treated (B,C), and propamidine isethionate-treated (D,E) corneas. H&E staining of control (F), PHMB-treated (G,H), and propamidine isethionate-treated (I,J) corneas. SEM images of control (K), PHMB-treated (L,M), and propamidine isethionate-treated (N,O) corneas. Arrows indicate neovascularization and circles indicate corneal erosion and edema area.

H&E staining {#s0085}
------------

Histological sections of the corneas were observed by H&E staining. In control corneas treated with PBS, no obvious changes were observed ([Fig. 1](#f0005){ref-type="fig"}F). However, massive inflammatory cell invasion and neovascularization were observed after 0.02% PHMB injection ([Fig. 1](#f0005){ref-type="fig"}G). With 0.01% PHMB, the stroma was thickened, but no inflammatory cells were observed ([Fig. 1](#f0005){ref-type="fig"}H). In corneas injected with 0.1% propamidine isethionate, enlarged stromal spaces containing few inflammatory cells were observed ([Fig. 1](#f0005){ref-type="fig"}I), while no obvious changes were observed with 0.05% propamidine isethionate treatment ([Fig. 1](#f0005){ref-type="fig"}J).

Scanning electron microscopy {#s0090}
----------------------------

With PBS treatment, the collagen fibrils of the stroma were regularly arranged ([Fig. 1](#f0005){ref-type="fig"}K). Arrangements of collagenous lamellae were distorted with 0.02% PHMB ([Fig. 1](#f0005){ref-type="fig"}L), while no structural damage was observed after 0.01% PHMB ([Fig. 1](#f0005){ref-type="fig"}M). There were also disarrangements of collagen fibrils with 0.1% propamidine isethionate injection ([Fig. 1](#f0005){ref-type="fig"}N), but no structural change was found after 0.05% propamidine isethionate treatment ([Fig. 1](#f0005){ref-type="fig"}O).

Corneal endothelium toxicity {#s0095}
----------------------------

We used SM to count the endothelial cells after intrastromal injection of PHMB or propamidine isethionate. Unfortunately, the 0.02% PHMB images were too blurry for analysis, and the endothelial cells could not be counted. However, specular microphotographs were obtained for the PBS, 0.01% PHMB, 0.1% propamidine isethionate, and 0.05% propamidine isethionate treatments ([Fig. 2](#f0010){ref-type="fig"}), and the cell densities were 3476.7 ± 32.4, 3185.7 ± 86.8, 3327.7 ± 95.3, and 3431.0 ± 57.9 cells/mm^2^, respectively (All *P* \> 0.05 vs. the control (PBS)). We observed cytotoxicity to corneal endothelial cells with 0.02% PHMB intrastromal injections, while intrastromal injection with 0.01% PHMB, 0.1% propamidine isethionate, and 0.05% propamidine isethionate did not cause significant decreases in corneal endothelial cells.Fig. 2Specular microscopy examination. Endothelial cell counts were measured 7 days after intrastromal injection. Analyzable images were only obtained for PBS, 0.01% PHMB, and 0.1% and 0.05% propamidine isethionate. Data are presented as the mean ± SD (n = 3). All *P* \> 0.05 vs. the control (PBS).

TUNEL assay {#s0100}
-----------

TUNEL-positive keratocytes, which indicate keratocyte apoptosis, were detected with 0.02% PHMB and 0.1% propamidine isethionate treatment, while no keratocyte apoptosis was observed with 0.01% PHMB and 0.05% propamidine isethionate ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3TUNEL assay. TUNEL-positive cells are denoted by arrows.

Cell viability assay {#s0105}
--------------------

PHMB and propamidine isethionate-treated corneal stromal keratocytes and endothelial cells exhibited significant dose- and time-dependent decreases in viability ([Fig. 4](#f0020){ref-type="fig"}). PHMB had higher cell toxicity compared with propamidine isethionate. In a previous report, the combination of a low (0.00125%) concentration of PHMB with the autophagy inhibitors showed low cytopathic effects on human corneal cells and high cytopathic effects on *Acanthamoeba* cells [@b0055]. Therefore, we used 0.00125% as our lowest concentration for PHMB in the WST-1 assay. When the PHMB concentration was decreased to 0.00125%, almost no toxicity was observed in corneal stromal keratocytes or endothelial cells (*P* \< 0.05). Similarly, when the propamidine isethionate concentration was decreased to 0.05%, almost no toxicity was observed in corneal stromal keratocytes cells (*P* \< 0.05).Fig. 4Cell viability (WST-1) assay. (A) Stromal keratocyte viability with different PHMB concentrations. (B) Endothelial cell viability with different PHMB concentrations. (C) Stromal keratocyte viability with different propamidine isethionate concentrations. (D) Endothelial cell viability with different propamidine isethionate concentrations. Data are presented as the mean ± SD (n = 5). \**P* \< 0.05 and \*\**P* \< 0.01 vs. the control (PBS).

Discussion {#s0110}
==========

Previous studies have demonstrated that diffuse and deep acanthamoeba cyst infiltration increases the need for therapeutic keratoplasty [@b0070]. Intrastromal injection with antibiotics has been used to treat deep bacterial and fungal keratitis, but intrastromal injection of antiamoebic agents has never been tested for the treatment of deep stromal AK. Theoretically, intrastromal injection of PHMB or propamidine isethionate may be an alternative treatment for patients with deep stromal AK who are unresponsive to topical anti-*Acanthamoeba* agents, decreasing the need for therapeutic keratoplasty. In addition, in patients requiring therapeutic penetrating keratoplasty (PKP), graft failure associated with AK recurrence due to residual viable cysts inside the recipient corneal stroma is not uncommon. Pre-operative intrastromal injection with PHMB or propamidine isethionate could potentially eradicate cysts in the deep stroma, reducing recurrence rates after PKP. However, there is limited data on the toxicity of PHMB and propamidine isethionate when administered via intrastromal injection. In this study, we investigated the *in vivo* and *in vitro* corneal toxicities of different concentrations of PHMB and propamidine isethionate, in an attempt to identify effective but nontoxic concentrations for intrastromal injection.

Conventional AK treatment concentrations are 0.02% PHMB and 0.1% propamidine isethionate [@b0010]; however, we observed significant corneal toxicity at these concentrations. Conversely, intrastromal injection of 0.01% PHMB or 0.05% propamidine isethionate was safe for the corneas. In clinical treatment, 0.02% PHMB and 0.1% propamidine isethionate will encounter serial dilution after administration. In an actual eye, 7 min after application, the concentration drops by more than half as a result of tear turnover, suggesting that 0.01% PHMB and 0.05% propamidine isethionate should be able to effectively treat AK [@b0075].

Our results revealed that corneal toxicity increases with higher concentrations of PHMB and propamidine isethionate. PHMB concentrations higher than 0.02% and propamidine isethionate concentrations higher than 0.1% had significant corneal toxicity. Previous report also revealed that 0.02% PHMB resulted in significantly decreased viability for human corneal epithelial and endothelial cells [@b0080]. In our study, 0.01% PHMB also caused decreased viability; however, in the absence of normal physiological eye function, this *in vitro* test could overestimate PHMB toxicity. In animal models, cornea exposure to sustained high concentrations of medications are not common. Moreover, we only give single dose of intrastromal injection in this study, the cytotoxicity is not as high as that *in vitro.*

Although the results suggest that intrastromal injection of 0.01% PHMB and 0.05% propamidine isethionate are safe adjuvant therapies for deep AK, this study has some limitations. First, some *Acanthamoeba* strains are highly resistant to PHMB, and therefore may not respond to treatment [@b0075]. However, since the evaluation of the toxicity of corneal intrastromal injections has been established, other antiamoebic agents can be tested for these resistant strains [@b0085]. Second, an animal model of AK infection is required to evaluate the true effects and pharmacokinetic parameters of corneal intrastromal injection. Future studies in this model system could help determine the appropriate concentrations for intrastromal injection depending on infectious status.

Conclusion {#s0115}
==========

In conclusion, to the best of our knowledge, this is the first study to demonstrate safe concentrations of PHMB and propamidine isethionate for corneal intrastromal injection in rabbit eyes. *In vivo* and *in vitro* studies suggest that intrastromal injection of 0.1 mL of 0.01% PHMB or 0.05% propamidine isethionate is safe for the corneas. These parameters should be tested in an animal model of AK to evaluate the effectiveness of treatment. Moreover, propamidine isethionate has a relatively low toxicity and could be considered for intrastromal injection in deep recalcitrant AK before further evidence is found.

Compliance with ethics requirements {#s0120}
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